GLP-1 drugs and SIBO: what the new research reveals
Meta:
- Category: Conditions
- Author: D2
- Date: March 2, 2026
- Read Time: 8 min
- Tags: [SIBO, GLP-1, Ozempic, Mounjaro, Gut Health, Medication Side Effects]
Quick answer
Multiple 2025 studies link GLP-1 receptor agonists (Ozempic, Mounjaro, Wegovy) to increased SIBO risk, especially after a year of use. The mechanism appears to be slowed gastric emptying and altered motility. If you are on these drugs and noticing new bloating or altered bowel patterns, SIBO testing is worth discussing with your clinician.
The GLP-1 explosion
GLP-1 receptor agonists have transformed diabetes and obesity treatment; Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are now household names. As usage has exploded, researchers are documenting gut-related side effects that were not visible in earlier trials.
What the new studies found
At Digestive Disease Week 2025, multiple research groups presented data on GLP-1 drugs and SIBO:
- A global retrospective multicenter cohort analysis (PMID: 40941750) was the first large-scale study identifying increased SIBO incidence with GLP-1/GIP medications.
- An association study (DOI: 10.1177/26345161251353437) linked GLP-1 receptor agonist use to both SIBO and IMO (intestinal methanogen overgrowth).
- Timing data suggests the risk is elevated within the first year of use.
The likely mechanism
GLP-1 drugs work partly by slowing gastric emptying, which is why people feel full longer and eat less. Slowed transit in the upper GI tract creates conditions where bacteria overgrow in the small intestine. Food lingers longer in the small bowel, and bacteria have more time to ferment carbohydrates. Overgrowth establishes from there.
I see the same mechanism in other motility disorders that predispose to SIBO. The small intestine is supposed to stay relatively clean between meals. Slow it down and you give bacteria a place to set up shop.
Who should pay attention
Discuss SIBO testing with your clinician if you have been on a GLP-1 drug for six or more months and you are experiencing new or worsening gut symptoms. Watch for bloating after meals, excessive gas, altered bowel patterns (diarrhea or constipation or alternating between them), and abdominal discomfort.
What to do
- Do not stop your medication without medical guidance. These drugs have important benefits.
- Track your symptoms. Note when they started and what triggers them.
- Ask your clinician about breath testing. Hydrogen and methane breath tests can identify SIBO and IMO.
- Consider motility support. If SIBO is identified, prokinetics may help prevent recurrence.
The bottom line
GLP-1 drugs are significant for many people; They are not risk-free, and gut motility changes are real. The new research does not mean you should avoid them; It means you should be informed and monitor for symptoms.
Sources
- Diagnostic Evaluation of SIBO Risk with GLP-1/GIP Agonists (PMID: 40941750)
- GLP-1 Receptor Agonist Use Associated with SIBO and IMO (DOI: 10.1177/26345161251353437)
- DDW 2025 Poster Presentations on GLP-1 and SIBO
Medical disclaimer: This article is educational only and is not medical advice. Consult your healthcare provider before changing any medication regimen.